Direct administration of an adenoviral vector expressing cytes exposed to AdCMV.CD and 5FC were transferred to the cytosine deaminase gene (AdCMV.CD) to tumors of cultures of CT26 mouse colon carcinoma cells, the CT26 colon carcinoma cells, with concomitant systemic adminisviability was reduced by 80%. To show that this regional tration of 5-fluorocytosine (5FC), results in local production AdCMV.CD/5FC prodrug strategy can suppress tumor of 5-fluorouracil (5FU) and suppression of tumor growth.
Introduction
Metastasis to the liver is the most common cause of death for patients with colorectal carcinoma. 1 The current therapy for colorectal cancer includes systemic or regional chemotherapy with 5-fluorouracil (5FU) or floxuridine (FUDR) which is limited by its adverse effects. [1] [2] [3] [4] One new therapeutic approach that takes advantage of the effectiveness of 5FU while minimizing systemic toxicity is an enzyme/prodrug combination using cytosine deaminase (CD) and 5-fluorocytosine (5FC). CD catalyzes the conversion of 5FC, a nontoxic antifungal drug into 5FU, a chemotherapeutic agent widely used in the treatment of colorectal cancer. [5] [6] [7] When the CD gene is transferred to the tumor cells, and the animals treated with 5FC, high local concentrations of 5FU are produced by intratumoral conversion of 5FC into 5FU. The effectiveness of this Correspondence: RG Crystal Received 3 July 1997; accepted 18 November 1997 strategy has been demonstrated in animal models using ex vivo transduced tumor cells 6, 8, 9 and using direct administration of adenoviral vector-mediated CD enzyme delivery. 10, 11 To apply this strategy to the common clinical scenario of multiple metastasis, we hypothesize that the widespread delivery of the gene coding for CD to the normal parenchymal cells of the liver will convert 5FC into 5FU on a regional basis and suppress tumor growth in vivo. Consistent with this concept, intrahepatic administration of an adenoviral vector expressing the CD gene to a limited region of the liver can significantly reduce the growth of human tumors in the liver of immunodeficient mice receiving 5FC. 11 The present study takes the next step -the widespread delivery of an adenovirus vector expressing the CD gene to the entire liver, ie enabling the majority of hepatocytes to be able to convert 5FC to 5FU, thus theoretically 'bathing' the liver in the chemotherapeutic agent. We have accomplished this by intravenous administration of a recombinant adenovirus vector expressing CD, a route which delivers more than 90% of the virus to the liver. [12] [13] [14] The data demonstrate that normal hepatocytes can convert 5FC into 5FU after infection with adenoviral vector expressing the CD gene (AdCMV.CD) and subsequent systemic treatment with 5FC. Importantly, using a mouse model of liver metastasis, we observed that this strategy caused significant suppression of growth of syngeneic colon carcinoma cells metastatic to the liver, thus demonstrating the feasibility of using normal parenchymal cells as targets for gene prodrug strategies.
Results

Gene transfer following intravenous administration
In the context that intravenous administration of Ad vectors results in Ͼ90% of the vector expression in the liver, the simplest strategy to administer Ad vectors to treat colon carcinoma metastases to the liver is to administer the vector intravenously. To evaluate whether this will result in gene transfer to intrahepatic tumors as well as hepatocytes, the AdCMV.␤gal vector was administered intravenously to mice with pre-established syngeneic colon carcinoma tumors. Strikingly, while there was extensive gene transfer and expression of ␤gal in the hepatocytes, there was little gene transfer to the tumors, except for the rim of cells on the tumor surface ( Figure  1 ). This observation led us to the concept that gene transfer to hepatocytes was much more feasible compared with gene transfer to a tumor within the liver. More specifically, the use of the hepatocytes to transfer the CD gene could serve as the source for production of high local concentrations of 5FU in the liver.
Cytosine deaminase enzyme activity in vitro
To demonstrate that the strategy of using hepatocytes to produce 5FU would work, it was first necessary to show that AdCMV.CD infection of hepatocytes would mediate conversion of 5FC to 5FU. To accomplish this, cultured primary rat hepatocytes were infected with AdCMV.CD, treated with 5FC for 0-3 days, and the conversion of 5FC into 5FU in the cell culture supernatant was measured using a spectrophotometric assay (Figure 2) . The AdCMV.CD-treated hepatocytes demonstrated a timedependent conversion of 5FC into 5FU over 3 days, with 70% conversion by day 3. Control hepatocytes infected with AdCMV.␤Gal showed no conversion of 5FC to 5FU.
HPLC analysis was used to confirm that the measured conversion was due to 5FU generation. The supernatants of the hepatocyte cultures infected with AdCMV.CD and exposed to 5FC showed two peaks, identified as 5FC and 5FU by comparison with the standards (Figure 3a) . Other possible metabolites, such as 5-fluorouridine and 5-fluoro-2Ј-deoxyuridine were not observed. Quantitative analysis showed a time-dependent generation of 5FU and a concomitant time-dependent decrease in 5FC ( Figure  3b ).
Viability of hepatocytes
One possible limitation in using hepatocytes to generate the 5FU to treat local tumors is that there would be concomitant toxicity to the hepatocytes. To determine if there was toxicity to the hepatocytes secondary to the AdCMV.CD plus 5FC-mediated generation of 5FU, primary rat hepatocytes were exposed to AdCMV.CD plus 5FC and viability of the hepatocytes assessed on each day of the cell culture by counting cell numbers using trypan blue exclusion assay. While there was a decrease in viability over time for all groups, the viability of the AdCMV.CD plus 5FC-treated group was identical to all of the control groups, including untreated cells, cells exposed to AdCMV.␤gal + 5FC, and cells exposed to 5FC alone (P Ͼ 0.7, all comparisons; Figure 4 ).
Toxicity of hepatocyte supernatant for tumor cells
While the AdCMV.CD plus 5FC treatment of primary hepatocytes was not toxic to the hepatocytes, the supernatant of the treated hepatocytes was toxic to colon carcinoma cells ( Figure 5 ). In this regard, transfer of the supernatant from AdCMV.CD plus 5FC treated hepatocyte cultures induced significant toxicity of the CT26 cells by day 1 (P Ͻ 0.001, AdCMV.CD plus 5FC supernatant to AdCMV.␤gal plus 5FC supernatant). In contrast, no toxicity was observed over 3 days with supernatant from control hepatocytes that had been infected with the AdCMV.␤gal control virus and treated with 5FC (P Ͼ 0.2, for all 3 days in comparison with day 0).
Cytosine deaminase enzyme activity in vivo
Evaluation of cytosine deaminase enzyme activity in liver extracts from mice that received AdCMV.CD intravenously demonstrated that a dosage of 10 9 plaque- forming units (p.f.u.) resulted in an in vitro conversion of 3 H 5FC into 3 H 5FU of about 58 ± 15% over 24 h. In contrast, control animals treated with intravenous AdCMV.␤gal showed only background activity of 4 ± 1% in the in vitro assay. 5FC compared with all groups). Tumor size in control groups comprising animals treated with AdCMV.CD only, treated with 5FC only, or untreated had similar tumor burdens at 15 days (P Ͼ 0.5, all comparisons). No deaths were observed from treatment with the adenovirus vectors or from the combination of adenovirus and 5FC or 5FC alone.
Discussion
The present study evaluates a regional strategy for in vivo prodrug gene therapy, where the gene coding for the enzyme that converts the prodrug to the active chemotherapeutic agent is transferred to the normal tissue, not the tumor. The strategy is based on the knowledge that: (1) [12] [13] [14] and the demonstration in the present study that very little goes to metastatic colon carcinoma tumors within the liver, the strategy is focused on the hepatocytes expressing the CD gene, converting the 5FC to 5FU, and secreting sufficient amounts of 5FU to promote toxicity of nearby tumor cells without concomitant hepatocyte toxicity. The data demonstrate that this can be achieved, with in vitro data showing AdCMV.CD-infected hepatocytes exposed to 5FC converted the 5FC to 5FU and exported sufficient amounts of 5FU to induce toxicity of cultured colon carcinoma cells, but not of cultured hepatocytes. Importantly, intravenous AdCMV.CD resulted in the expression of active CD in the liver, and when the animals were treated with the prodrug 5FC, there was suppression in the growth of tumors of metastatic syngeneic colon carcinoma cells.
5FU generation in hepatocytes
One critical question to answer was: do hepatocytes have the capacity to convert 5FC into 5FU and release active 5FU or metabolites into their environment? In vivo, 5FU metabolism is mediated mainly in the liver, where the enzyme dihydrouracil dehydrogenase (DHU-DH) converts 5FU into 5-fluorodihydrouracil. 15 Since the liver has a high concentration of this enzyme, it was not known whether hepatocytes that have been directed to express the enzyme cytosine deaminase would be able to convert 5FC into 5FU and secrete 5FU and/or its metabolites into the environment. Thus, one important observation of this study was the demonstration by HPLC analysis that primary rat hepatocytes treated in vitro with AdCMV.CD and exposed to 5FC can release 5FU into the local milieu. Interestingly, other intracellular metabolites of 5FU that have been demonstrated in tumor cells, such as 5-fluorouridine and 5-fluoro-2Ј-deoxyuridine, 8, 16 were not observed in this study.
Cytosine deaminase prodrug 'in vivo' strategy One strategy to use the CD/5FU approach is to directly transduce tumor cells with the CD gene. 5 8, 9, 17 Consistent with this concept, in mice receiving systemic 5FC, the growth of subcutaneous tumors transduced with the CD gene ex vivo or in vivo is decreased. For the in vivo studies, it is likely that at least some of the antitumor effect in solid tumors results from secreted 5FU by the CD transduced cells, and the ability of 5FU to diffuse into the neighboring cells, 8, 10, 16, 17 since it is difficult to transfect a majority of the tumor cells in vivo. The present study takes advantage of this bystander effect by transducing the hepatocytes in the metastatic liver with AdCMV.CD, with the hepatocytes secreting 5FU into the local environment.
Based on this concept, we previously demonstrated in a colorectal metastasis model of a human tumor cell line in immunodeficient mice, that pre-established hepatic tumors treated by direct administration (to the liver parenchyma approximately 1 cm from the tumor) of a recombinant adenoviral vector containing the cytosine deaminase, and systemic treatment with 5FC resulted in substantial tumor regression. 11 However, direct, local intrahepatic administration of a gene transfer vector is not applicable to the common clinical scenario of microscopic metastases diffusely distributed in the liver. Since tumor cells metastatic to the liver at an early stage of growth will be surrounded by hepatocytes, we hypothesized that transfer of the CD gene to hepatocytes in the context of systemic administration of 5FC would result in production of 5FU in significant amounts to suppress tumor growth in a local environment. As demonstrated in the present study, while gene transfer to hepatic metastases is a major challenge, gene transfer with an adenovirus vector to hepatocytes surrounding a tumor is relatively easy. Based on this regional delivery strategy, there was significant suppression of the tumor growth in the liver after intravenous administration of AdCMV.CD and systemic treatment with 5FC. Since the tumor itself is likely not transduced by the intravenous application of the adenovirus vector, and based on the in vitro studies with hepatocytes, it is most likely that the antitumor effect is due to secreted 5FU from hepatocytes.
Possible clinical applications
In an attempt to improve the accessibility of metastases to the liver, hepatic artery chemotherapy (HAC) has been explored for many years and demonstrated promising results for the therapy of hepatic colorectal metastases. 3, 4 The advantage of HAC is that a higher drug level at the sites of metastasis can be achieved. One of the arguments for the regional delivery of 5FU or other effective agents (eg FUDR) is that hepatic metastases of more than 3 mm in diameter derive their blood from the hepatic artery, while tumors smaller than 0.2 mm show no visible blood vessels and are supplied by sinusoidal blood flow. [18] [19] [20] [21] The strategy of the presented study focuses on the treatment of small tumors (Ͻ10 6 cells) that are in a 'prevascular' phase. Since the 5FU converted by the hepatocytes is likely secreted into the interstitial space, this could be a different mechanism to reach hepatic micro-metastases compared with the HAC approach, ie the two strategies may be synergistic.
One of the most common clinical problems with HAC is biliary toxicity, which is believed to result from the high local doses of chemotherapy, since the biliary ducts derive their blood almost exclusively from the hepatic artery. 22 Toxicity of the AdCD/5FC regional strategy in a clinical setting has to be proven, but recent animal data revealed no toxicity to the liver. 11 Finally, HAC therapy using an implantable pump requires a major surgical procedure. 3, 4 In contrast, the strategy using a single intravenous injection of an adenoviral vector carrying the gene for CD and the convenient oral application of 5FC provides a much simpler therapy.
The clinical application of our strategy will depend largely on the amount of adenovirus that can be delivered safely to the liver. Possible limiting factors can be the neutralizing antibodies against the adenovirus in humans that might limit the re-administration of the vector. Although this has been shown to be the case in rats 23 there are currently no clinical data available that investigate these effects in the application of recombinant adenovirus in humans. Further studies will be necessary to investigate this in humans.
Materials and methods
Recombinant adenovirus vectors
The AdCMV.CD vector is an E1a
, Ad5-based adenoviral vector with an expression cassette in the E1 region containing a modified E. coli 1.6 kb CD gene driven by the cytomegalovirus major immediate-early promotor. 10 The control vector AdCMV.␤Gal is similar, except that it contains the ␤-galactosidase (␤gal) reporter gene instead of the CD gene. 24 The vectors were amplified and titrated as previously described. 25, 26 Cell cultures The CT26 murine colon carcinoma cell line, syngeneic for Balb/c, was grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO-BRL, Gaithersberg, MD, USA) with 10% fetal calf serum (Biofluids, Rockville, MD, USA), 50 units/ml penicillin G, 50 g/ml streptomycin and 2 mm glutamine. Primary rat hepatocytes were prepared as described by Jaffe et al. 27 In brief, primary hepatocytes were established from 250-300 g male SpragueDawley rats (Charles River Laboratories, Wilmington, MA, USA), by using hepatic perfusion with collagenase solution (Type IV; Sigma, St Louis, MO, USA) as described by Seglen, 28 and cultured in DMEM mixed 1:1 with Waymouth's medium (GIBCO) including dexamethasone (20 ng/ml; Sigma), insulin (5 g/ml), transferrin (5 g/ml), selenous acid (5 ng/ml, ITS; Collaborative Research, Bedford, MA, USA), gentamycin (10 g/ml), penicillin (50 units/ml) and streptomycin (50 g/ml). Hepatocytes were used within 24 h of isolation.
Quantification of conversion of 5FC to 5FU
To quantify the in vitro conversion of 5FC into 5FU in primary hepatocytes in vitro, cultured primary rat hepatocytes (10 6 cells) were infected with the AdCMV.CD vector or the control vector AdCMV.␤Gal (MOI 20, 60 min). Cells were washed with phosphate-buffered saline (PBS), pH 7.4 to remove unincorporated virus and then grown in regular culture medium containing 5 mm 5FC. On days 0-3, 50 l of cell culture supernatant was transferred into 1 ml of 0.1 n HCl, optical density was measured at 255 and 290 nm, the concentration of 5FC and 5FU was calculated with the percentage conversion of 5FC to 5FU calculated as 5FU × 100/(5FU + 5FC). 29, 30 Viability of the hepatocytes was assessed by removing the cells from the plate with trypsin, and counting the number of viable cells after adding trypan blue.
To evaluate the ability of the AdCMV.CD vector to express a functional CD enzyme in the liver in vivo, AdCMV.CD (10 9 p.f.u.) was administered intravenously into the jugular vein of Balb/c mice in a total volume of 100 l. Animals were killed after 3 days, livers were homogenized in 500 l of 100 mm Tris-HCl pH 7.8, 1 mm ethylenediaminetetra-acetic acid (Sigma) pH 7.8, 1 mm dithiothreitol, centrifuged (14 000 g, 20 min) and the supernatants collected. Lysates (30 g protein) were incubated with 10 l of 3 H 6-fluorocytosine (0.5 Ci/mmol; Sigma) at 37°C for 24 h. Enzyme activity was assessed using thin layer chromatography. 5 Cytosine deaminase activity was expressed as the percentage conversion of 
HPLC
To verify the conversion of 5FC into 5FU by hepatocytes, and to detect other possible metabolites, HPLC analysis was used to assess the supernatants from primary rat hepatocytes exposed to AdCMV.CD and 5 mm 5FC. Samples were centrifuged (16 000 g, 10 min) and supernatants were diluted 1:10 in running buffer (50 mm ammonium phosphate/0.1% triethylamine, pH 2.1). These preparations (100 l) were directly analyzed by HPLC on a Bondapak C18 column (125 Å, 10 m, 3.9 × 300 mm; Waters, Milford, MA, USA) using minor modifications of the method of Huber et al. 8 Samples were eluted isocratically with 50 mm ammonium phosphate/0.1% triethylamine, pH 2.1 at a flow rate of 1 ml/min. The UV absorbance was detected by a model 484 tunable monitor (Waters) at 260 nm. Standards included 5FU, 5FC, and possible metabolites 5-fluorouridine and 5-fluoro-2Ј-deoxyuridine (Sigma).
Toxicity assay (MTT)
To evaluate the ability of supernatants of AdCMV.CD + 5FC-treated hepatocytes to induce toxicity of colon carcinoma cells, supernatants from hepatocytes exposed to AdCMV.CD and 5FC were transferred to CT26 cells in 96-well plates and incubated for 48 h. The viability of the CT26 cells was assessed using the microculture tetrazolium assay (MTT) performed by adding 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (5 mg/ml; thiazolyl blue; Sigma) in PBS to the culture for 4 h at 37°C. 31 The supernatant was removed, 150 l of dimethylsulfoxide (Sigma) was added, and after 20 min at 23°C, the absorbance at 540 nm was determined. Viability was calculated as percentage absorbance compared with untreated cells.
In vivo model
To evaluate the regional effect of systemic administration of AdCMV.CD and 5FC on local metastases of colon carcinoma in the liver, a model for metastatic colon carcinoma was established in Balb/c mice (Charles River Laboratories by injecting 10 4 CT26 colon carcinoma cells directly into the tip of the left lobe of the liver. After 24 h, AdCMV.CD (10 9 p.f.u.) was administered in a total volume of 100 l PBS intravenously into the left jugular vein. The following day, treatment with 5FC (500 mg/kg, in PBS) interperitoneal was started with daily injections for 10 days. In each treatment group (n = 5 per group), the animals were killed on day 15 and tumor size was measured by caliper in three dimensions.
In vivo expression of genes transferred by intravenous administration of adenovirus vectors to the liver To evaluate the relative distribution of gene expression within the liver after intravenous administration of an adenovirus vector, 10 9 p.f.u. of AdCMV.␤gal was administered intravenously into Balb/c mice containing metastases of CT26 cells. The CT26 cells (10 4 ) were administered as described above, 4 days before vector administration. The vector was administered intravenously, and after 72 h, the animals were killed, the liver removed and snap frozen in Tissue Tek OCT compound (Sakura, Finetek, Torrance, CA, USA). Five micrometer sections were analyzed for the presence of ␤gal, the lacZ gene product, by histochemical analysis using X-gal substrate (5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside; Boehringer Mannheim, Indianapolis, IN, USA) as previously described. 32 Briefly, slides were air dried and exposed to 5 mm K 4 Fe(CN) 6 , 5 mm K 3 Fe (CN) 6 (Sigma) and 2 mm MgCl 2 in phosphate-buffered saline, pH 7.4 containing 500 g/ml of the X-gal substrate. The liver slides were then counterstained with nuclear fast red. The lacZ gene expression is positive when a nuclear/perinuclear blue color is observed.
Statistical analysis
Results are presented as mean ± standard error of the mean. All comparisons were made using the unpaired two-tailed Student's t test.
